Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy.

[1]  J. Blasko,et al.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. , 2000, Seminars in urologic oncology.

[2]  W Cavanagh,et al.  Palladium-103 brachytherapy for prostate carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[3]  G. Hanks.  Conformal radiotherapy for prostate cancer , 2000, Annals of medicine.

[4]  C. King,et al.  Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. , 2000, International journal of radiation oncology, biology, physics.

[5]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Ling,et al.  Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[8]  J. Moul,et al.  Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[9]  R. Stock,et al.  The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, Seminars in surgical oncology.

[10]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[11]  A. K. Levinson,et al.  The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. , 1997, Urology.

[12]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[13]  K. Wallner,et al.  1011 Palladium-103 brachytherapy for clinical prostate carcinomas , 1997 .

[14]  W Cavanagh,et al.  Should brachytherapy be considered a therapeutic option in localized prostate cancer? , 1996, The Urologic clinics of North America.

[15]  T. Schultheiss,et al.  Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. , 1995, The Journal of urology.

[16]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[17]  A. V. von Eschenbach,et al.  The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy , 1994, Cancer.

[18]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[19]  C. Mettlin,et al.  Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American college of surgeons commission on cancer , 1993, CA: a cancer journal for clinicians.

[20]  D. Cox.  Regression Models and Life-Tables , 1972 .

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .